- Home
- ERNA vs EVGN Comparison
ERNA vs EVGN Comparison
Compare ERNA & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERNA | EVGN |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 9.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ERNA | EVGN |
|---|---|---|
| Price | $1.19 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | ★ 187.7K | 58.6K |
| Earning Date | 11-07-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,000.00 | ★ $8,016,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.19 |
| 52 Week Low | $1.08 | $0.93 |
| 52 Week High | $11.07 | $2.42 |
Technical Indicators
Market Signals| Indicator | ERNA | EVGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 44.96 |
| Support Level | $1.15 | $1.02 |
| Resistance Level | $1.29 | $1.10 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 40.63 | 39.29 |
Price Performance
Historical ComparisonAbout ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.